[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autosomal-dominant-polycystic-kidney-disease-adpkd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autosomal-dominant-polycystic-kidney-disease-adpkd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,66,94,117,144,166,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100642708","dietary-modulation-of-urinary-mcp-1-in-adpkd-100642708",false,"NCT07651397","Dietary Modulation of Urinary MCP-1 in ADPKD","Open Labeled , Randomized, Controlled, Crossover Trial on the Effect of a Carbohydrate Restricted Plant Dominant Diet on MCP-1 Mediated Inflammatory Signaling in Autosomal Dominant Polycystic Kidney Disease","Inclusion Criteria:\n\n1. Age ≥18\n2. Diagnosis of ADPKD based on established clinical or genetic criteria (PKD 1\u002FPKD2)\n3. Estimated glomerular filtration rate (eGFR) between 45 and 90 mL\u002Fmin\u002F1.73 m²\n4. Mayo Imaging Classification class 1C-1E based on MRI-derived height-adjusted total kidney volume.\n5. Stable kidney function, defined as no acute kidney injury and no decline in eGFR \\>20% within the preceding 3 months\n6. Stable antihypertensive and chronic medications for at least 4 weeks prior to enrollment\n7. Ability and willingness to adhere to the prescribed dietary intervention\n8. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m² or requirement for dialysis\n2. History of kidney transplantation\n3. Significant albuminuria, defined as urine albumin to creatinine ratio (UACR) \\>300 mg\u002Fg\n4. Poorly controlled or unstable diabetes mellitus (e.g., HbA1c \\>8% or clinically significant glycemic variability or frequent hypoglycemia)\n5. Use of Tolvaptan at the time of screening or within the study period\n6. Current adherence to a ketogenic or carbohydrate restricted diet\n7. Unintentional weight loss \\>5% within the preceding 3 months\n8. Active infection, inflammatory disease, or malignancy that may influence inflammatory markers\n9. Current use of systemic corticosteroids or immunosuppressive therapy\n10. Active or symptomatic nephrolithiasis\n11. Serum bicarbonate \\\u003C20 mmol\u002FL\n12. Pregnancy or breastfeeding\n13. Known eating disorder or condition limiting adherence to dietary interventions\n14. Participation in another interventional study within the previous 3 months\n15. Any condition that, in the opinion of the investigators, would interfere with study participation or interpretation of results","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"NA","Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and declining kidney function. Inflammatory pathways, including those mediated by monocyte chemoattractant protein-1 (MCP-1), are increasingly recognized as contributors to disease progression. Metabolic alterations in cystic epithelial cells may influence inflammatory signaling, suggesting a potential role for dietary interventions targeting metabolic pathways.\n\nThis study is a prospective, randomized, open-label crossover trial designed to evaluate the effect of a carbohydrate restricted, plant dominant dietary intervention on urinary MCP-1 levels in adults with ADPKD. Participants will be randomized to one of two sequences: dietary intervention followed by usual diet, or usual diet followed by dietary intervention, with a washout period between study phases. Each study period will last 12 weeks.\n\nThe primary objective is to assess within subject differences in urinary MCP-1\u002Fcreatinine ratio between the dietary intervention and usual diet conditions. Secondary outcomes include measures of metabolic parameters, insulin resistance, dietary adherence, and safety.\n\nThis study aims to explore whether a structured dietary approach may influence intrarenal inflammatory activity in ADPKD and provide preliminary data to inform future interventional studies.",[26],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":20},"2026-07-10",{"date":35,"type":20},"2029-01-01",{"name":37,"class":38},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100605324","phase-2-phase-2a-study-of-vx-407-in-participants-with-adpkd-who-have-a-subset-of-pkd1-gene-variants-aglow-100605324","NCT07161037","Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)","A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants","AGLOW","Key Inclusion Criteria:\n\n* A pre-existing diagnosis of ADPKD as defined in the protocol\n* Willing and able to comply with scheduled visits and other study procedures\n* Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL\u002Fm), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening\n* Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL\u002Fmin)\u002F1.73 square meter (m\\^2)\n\nKey Exclusion Criteria:\n\n* History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD\n* History of solid organ or bone marrow transplantation or nephrectomy\n* Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","65 Years",{"count":49,"type":20},24,[51],"PHASE2","The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.",[26],"RECRUITING","2026-06-11",{"date":57,"type":31},"2026-06-15",{"date":59,"type":31},"2025-11-19",{"date":61,"type":20},"2027-12-31",{"name":63,"class":64},"Vertex Pharmaceuticals Incorporated","INDUSTRY",43,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100570958","phase-1-phase-1-study-to-evaluate-the-safety-and-tolerability-of-intravenously-administered-pyc-003-100570958","NCT06714006","Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants With Confirmed PKD1 Mutation-associated Autosomal Dominant Polycystic Kidney Disease","Part A (SAD - Healthy Volunteers) Key Inclusion Criteria\n\n1. Adult aged 18 to 60 years (inclusive)\n2. At the discretion of the PI or designee, in good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening\n3. BMI ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and weight ≥ 50 kg.\n4. Non-smoker and must not have used any tobacco or nicotine products within 2 months prior to Screening.\n5. Clinical laboratory values within normal range or deemed not clinically significant by the PI\n6. eGFR ≥ 80 mL\u002Fmin\u002F1.73 m2 via the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) 2021 calculation\n7. Woman of childbearing potential (WOBCP) must agree to use an acceptable, highly effective, double barrier method of contraception from the start of Screening until study completion.\n8. Males must be surgically sterile (vasectomized for at least 6 months prior to first IP administration) or, if engaged in sexual relations with a WOCBP, must agree to use an acceptable, highly effective, double barrier method of contraception from the start of Screening until study completion.\n9. Females must agree not to donate ova from the first administration of IP until 30 days following study completion.\n10. Males must agree not donate sperm from the first administration of IP until 90 days following study completion.\n11. Able and willing to attend the necessary visits to the study site.\n12. Able and willing to adhere to caffeine, alcohol, and nicotine-containing product restrictions\n13. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\nPart A (SAD - Healthy Volunteers) Key Exclusion Criteria\n\n1. Females who are pregnant, breastfeeding, or plan to become pregnant during the course of the study.\n2. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.\n3. Has only 1 kidney or has received a kidney transplant.\n4. Blood donation or had significant blood loss (\\> 500 mL) within 30 days prior to the first administration of IP.\n5. Plasma donation within 7 days prior to the first administration of IP.\n6. Fever (body temperature \\> 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to first administration of IP.\n7. Infections requiring parenteral antibiotics within 6 months prior to Screening.\n8. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV antibody.\n9. History of life-threatening infection (e.g., meningitis).\n10. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP.\n11. Poor venous access.\n12. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.\n13. History of malignancy, except for non-melanoma skin cancer excised more than 1 year prior to Screening and cervical intraepithelial neoplasia that has been successfully cured more than 2 years prior to Screening.\n14. Abnormal electrocardiogram (ECG) findings at Screening, Day -3 to Day -1, or predose that are considered by the PI or designee to be clinically significant.\n15. History or presence of a condition associated with significant immunosuppression.\n16. Exposure to any drugs that cause significant immunosuppression (including experimental therapies as part of a clinical study) within 4 months or 5 half-lives (whichever is longer), prior to Screening.\n17. ALP, AST, and ALT \\> 1.5 × ULN at Screening or Day -3 to Day -1.\n18. History of borderline to low blood magnesium and potassium levels and\u002For Screening or Day -3 to Day -1 blood magnesium level \\\u003C 0.7 mmol\u002FL and potassium levels \\\u003C 3.5 mmol\u002FL.\n19. Active infection of the urinary tract (ie, kidney, bladder).\n20. Positive toxicology screening panel (urine test including qualitative identification of amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, methadone, opiates, phencyclidine, tetrahydrocannabinol \\[THC\\], tricyclic antidepressants), or alcohol breath test.\n21. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).\n22. Regular alcohol consumption defined as \\> 14 standard drinks per week for females and \\> 21 standard drinks for males (where 1 standard drink = 375 mL of mid-strength beer \\[3.5% alcohol\u002Fvolume\\], 100 mL wine \\[13.5% alcohol\u002Fvolume\\] or 30 mL of spirits \\[40% alcohol\u002Fvolume\\]) or \\> 4 standard drinks on any single day.\n23. Unwilling to abstain from alcohol for 48 hours prior to admission to the study site and for 48 hours prior to any follow-up visits.\n24. Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of IP.\n25. Use of (or anticipated use of) the following:\n\n    1. Any prescription drugs (other than hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device \\[IUD\\]) within 14 days prior to the first administration of IP and during the course of the study without prior approval of the PI and MM.\n    2. Any over-the-counter medication, herbal remedies, supplements or vitamins within 7 days prior to the first administration of IP and during the course of the study without prior approval of the PI and MM. Note: Paracetamol (i.e., up to 2000 mg per day) may be used for minor ailments during the study, at the discretion of the PI, without prior consultation with the MM.\n26. Unwilling to refrain from strenuous exercise (including weightlifting) for 48 hours prior to admission to the study site and for 48 hours prior to any follow-up visits.\n27. Anything that the PI considers would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.\n\nPart B and Part C (ADPKD Participants) Key Inclusion Criteria\n\n1. Male or female aged 18 to 65 years (inclusive) at the time of informed consent.\n2. ADPKD diagnosis as confirmed by the presence of genetic mutations associated with ADPKD, including, but not limited to, the presence of PKD1 mutation. Note: Where genotyping is not included the medical history for a participant, genotyping may be completed at Pre-Screening.\n3. Class 1C, 1D, or 1E per Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD (Irazabal et al. 2015) (based upon prior magnetic resonance imaging \\[MRI\\] or computed tomography \\[CT\\] scan obtained prior to Screening, or MRI obtained during Pre-Screening).\n4. BMI ≥ 18.0 and ≤ 35.0 kg\u002Fm2 and weight ≥ 50 kg.\n5. Non-smoker and must not have used any tobacco or nicotine products within 2 months prior to Screening.\n6. Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73 m2 via the CKD EPI 2021 calculation\n\n8\\. Hematology and serum chemistry results at Screening that meet the following criteria:\n\n1. Platelets \\> 150 × 10\\^9\u002FL\n2. Total white blood cell count \\> 3.0 × 10\\^9\u002FL\n3. Absolute neutrophil count \\> 1.5 × 10\\^9\u002FL\n4. Hemoglobin \\> 110 g\u002FL for females and \\> 120 g\u002FL for males\n5. Total and direct bilirubin \\\u003C 1.5 × ULN, unless elevated bilirubin is associated with a known benign condition (e.g., Gilbert's syndrome)\n6. Alanine aminotransferase (ALT) \\\u003C 1.5 × ULN\n7. Aspartate aminotransferase (AST) \\\u003C 1.5 × ULN\n8. Alkaline phosphatase (ALP) \\\u003C 1.5 × ULN\n9. Gamma-glutamyl transferase \\\u003C 2 × ULN\n\n   9.WOCBP must agree to use an acceptable, highly effective, double barrier method of contraception from the start of Screening until study completion\n\n   10\\. Males must be surgically sterile (vasectomized for at least 6 months prior to first administration of IP) or, if engaged in sexual relations with a WOCBP, must agree to use an acceptable, highly effective, double barrier method of contraception from the start of Screening until study completion\n\n   11\\. Females must agree not to donate ova from the first administration of IP until 30 days following study completion.\n\n   12.Males must agree not donate sperm from the first administration of IP until 90 days following study completion.\n\n   13\\. Able and willing to attend the necessary visits to the study site.\n\n   14\\. Able and willing to adhere to alcohol and nicotine-containing product restrictions\n\n   15\\. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\n   Part B and Part C (ADPKD Participant) Key Exclusion Criteria\n   1. Females who are pregnant, breastfeeding, or plan to become pregnant during the course of the study.\n   2. Presence of potentially confounding genetic mutations (per genotyping by a NATA accredited or equivalent diagnostic laboratory)including, but not limited to, the presence of PKD2, HNF1B, GANAB, IFT140, and\u002For DNAJB 11 mutations.\n   3. Use of (or anticipated use of) Tolvaptan and\u002For metformin administration within 30 days prior to the first administration of IP until study completion.\n   4. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.\n   5. Any renal or systemic pathology other than ADPKD or any other condition or prior therapy that in the opinion of the PI or designee would make the participant unsuitable for this study.\n   6. Has only 1 kidney or has a kidney transplant.\n   7. Blood donation or had significant blood loss (\\> 500 mL) within 30 days prior to the first administration of IP.\n   8. Plasma donation within 7 days prior to the first administration of IP.\n   9. Has received (or is anticipated to receive) cell therapy, gene therapy, or RNA therapy for any renal condition.\n   10. Fever (body temperature \\> 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to first administration of IP.\n   11. Infections requiring parenteral antibiotics within 6 months prior to Screening.\n   12. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV antibody.\n   13. History of life-threatening infection (e.g., meningitis).\n   14. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP.\n   15. Poor venous access.\n   16. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.\n   17. History of malignancy, except for non-melanoma skin cancer excised more than 1 year prior to Screening and cervical intraepithelial neoplasia that has been successfully cured more than 2 years prior to Screening.\n   18. Abnormal ECG findings at Screening, Day -3 to Day -1, or predose that are considered by the PI or designee to be clinically significant.\n   19. Abnormal vital signs findings at Screening that are considered by the PI or designee to be clinically significant.\n\n       Note: A hypertensive participant is eligible if on a stable antihypertensive regimen for ≥ 28 days prior to first administration of IP and the blood pressure adequately controlled (per PI discretion) prior to first administration of IP.\n   20. History or presence of a condition associated with significant immunosuppression.\n   21. Exposure to any drugs that cause significant immunosuppression (including experimental therapies as part of a clinical study) within 4 months or 5 half-lives (whichever is longer), prior to Screening.\n   22. History of borderline to low blood magnesium and potassium levels and\u002For Screening or Day -3 to Day -1 blood magnesium level \\\u003C 0.7 mmol\u002FL and potassium levels \\\u003C 3.5 mmol\u002FL.\n   23. Urine protein: creatinine ratio (UPCR) of \\> 50 mg\u002Fmmol.\n   24. Hematuria (urine protein: creatinine ratio \\> 30 mg\u002FmmoL, or hematuria \\> ++ on dipstick, or \\> 100 cells per high-power field on microscopy) and\u002For urinary abnormalities at Screening deemed by the PI or designee to be of moderate or higher severity.\n   25. Renal complications (eg, cyst rupture or cyst infections) within 6 weeks prior to first administration of IP.\n   26. Active infection of the urinary tract (ie, kidney, bladder).\n   27. Positive toxicology screening panel (urine test including qualitative identification of amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, methadone, opiates, phencyclidine, tetrahydrocannabinol \\[THC\\], tricyclic antidepressants), or alcohol breath test.\n   28. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).\n   29. Regular alcohol consumption defined as \\> 14 standard drinks per week for females and \\> 21 standard drinks for males (where 1 standard drink = 375 mL of mid-strength beer \\[3.5% alcohol\u002Fvolume\\], 100 mL wine \\[13.5% alcohol\u002Fvolume\\] or 30 mL of spirits \\[40% alcohol\u002Fvolume\\]) or \\> 4 standard drinks on any single day.\n   30. Unwilling to abstain from alcohol for 48 hours prior to admission to the study site and for 48 hours prior to any follow-up visits.\n   31. Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of IP.\n   32. Unwilling to refrain from strenuous exercise (including weightlifting) for 48 hours prior to admission to the study site and for 48 hours prior to any follow-up visits.\n   33. Anything that the PI considers would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.\n\n   Part D will be an extension study for participants that complete Part C.",true,{"count":75,"type":20},166,[77],"PHASE1","This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1 mutation-associated Autosomal Dominant Polycystic Kidney Disease (ADPKD) There are 4 parts in this study, i.e. Part A, Part B, Part C and Part D.",[26],[81,82,83],"PKD1","Autosomal Dominant Polycystic Kidney Disease","ADPKD","2026-06-04",{"date":86,"type":31},"2026-06-08",{"date":88,"type":31},"2025-04-07",{"date":90,"type":20},"2028-11",{"name":92,"class":64},"PYC Therapeutics",10,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100634107","radiological-and-clinical-evaluation-of-renal-embolization-using-evoh-in-dialysis-patients-with-autosomal-dominant-polycystic-kidney-disease-a-prospective-longitudinal-observational-study-100634107","NCT07535385","RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY","Inclusion Criteria:\n\n* aged over 18 and under 75\n* written informed consent\n* Patients with autosomal dominant polycystic kidney disease, with a kidney volume of between 2000 and 5000 mL, on dialysis, undergoing renal embolisation\n\nExclusion Criteria:\n\n• Contraindications to MRI without contrast (ferromagnetic implants, incompatible pacemakers, surgical clips, severe claustrophobia or other conditions that may interfere with MRI)","75 Years",{"count":102,"type":20},30,"OBSERVATIONAL","Autosomal dominant polycystic kidney disease (ADPKD) is an inherited cystic disorder characterised by the progressive degeneration of the renal parenchyma into cystic formations, with involvement of other organs to varying degrees and incidence (liver, pancreas and brain).\n\nThis condition is the most common inherited kidney disorder; in fact, it affects 1 in 400-1,000 births and has a prevalence of 5% among dialysis patients and an incidence of 10% among patients with end-stage renal failure in Europe. It is caused by mutations in the PKD1 or PKD2 genes, which are involved in the production of an abnormal protein that leads to tubular dysplasia.\n\nCystic degeneration leads to progressive loss of renal function, with the development of hypertension, haematuria and concomitant enlargement of the renal parenchyma. The progression of the disease is precisely marked by an increase in renal volume. The increase in the organ's overall volume is secondary to the development and enlargement of cysts, whilst the proportion of functioning renal parenchyma progressively decreases. For these reasons, the increase in renal volume over time is a powerful predictor of the risk of end-stage renal disease (ESRD).\n\nIn addition to its prognostic significance, the enlargement of the kidneys is itself a cause of complications. Indeed, the space occupied within the abdomen can become so extensive as to cause abdominal distension, malaise, pain, loss of appetite, constipation, nausea and vomiting, reduced diaphragmatic movement, breathing difficulties and lower back pain. Overall, patients' quality of life can be severely compromised.\n\nIt is not uncommon for the kidneys of patients with ADPKD to occupy the pelvic cavity, the preferred site for kidney transplant placement, which represents the optimal treatment option for the disease once ESRD has been reached. This situation, which is not uncommon, represents a temporary contraindication to kidney transplantation: delaying the procedure also has repercussions on the patient's survival.\n\nThe contraindication to transplantation due to anatomical unavailability has so far necessitated surgical nephrectomy (so-called 'debridement nephrectomy') as the sole preventive or pre-transplant therapeutic option. Nephrectomy carries the risks inherent in surgery, including haemorrhage, herniation of the abdominal wall, vascular complications of varying severity-such as arteriovenous fistulas, thrombosis, and vascular wall injury-and the risk of infection. Surgical nephrectomy also has a negative impact on the subsequent possibility of using the peritoneal membrane for dialysis (peritoneal dialysis) and, should blood transfusions be required to correct intraoperative blood loss, contributes to increasing the likelihood of the patient becoming immunised, with the associated risks of reduced availability of compatible donors (so-called hyperimmune patients), and, in any case, a higher risk of acute and chronic rejection, conditions that negatively impact transplant survival.\n\nGiven the high risks associated with nephrectomy, a non-invasive alternative has been proposed: reduction of renal volume via transcatheter arterial embolisation.\n\nRenal embolisation can be performed in the Interventional Radiology department via the controlled occlusion of renal vessels using a liquid embolisation agent composed of ethylene vinyl alcohol (EVOH). The literature reports the assessment of embolised patients using CT without contrast medium, but recent technological innovations allow for accurate and precise volumetric assessment of organs using MRI without contrast medium, with reduced inter-operator variability and without the need to subject the patient to ionising radiation during follow-up.",[26],"2026-04-10",{"date":108,"type":31},"2026-04-17",{"date":110,"type":31},"2020-08-17",{"date":112,"type":20},"2026-08-17",{"name":114,"class":115},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":116},"100627864","metabolic-impacts-of-ren-nu-a-dietary-program-for-polycystic-kidney-disease-100627864","NCT07454174","Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease","Short-Term Metabolic Impacts of Ren-Nu: A Dietary Program for Individuals With Polycystic Kidney Disease","PKD-KETO","Inclusion Criteria:\n\n* Adult (18 years or older)\n\n  * Diagnosis of ADPKD by a physician.\n  * Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73 m2 at screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n  * Appropriate control of blood pressure (i.e. entry reading \\\u003C140\u002F90) including the use of BP medications for diagnosis of hypertension.\n  * BMI ≥ 25 (accounting for muscle mass)\n  * Own an at-home blood pressure monitor (no brand requirements)\n  * Able to complete study-related activities (e.g., attend online classes, complete questionnaires, and proper use of medical devices)\n\nExclusion Criteria:\n\n* Intolerance or allergy to any of the ingredients in the provided medical food\n\n  * Severe or rare underlying health conditions may cause a safety risk when taking the medical food. Those underlying health conditions will be assessed by the enrolling physician and include but are not limited to:\n\n    * History of hyperkalemia\n    * Heart failure\n    * Liver cirrhosis\n    * Chronic kidney disease stage 4 or greater, or other renal condition that severely impairs bone mineral homeostasis.\n    * HIV infection\n    * Chronic drug or alcohol abuse\n    * Chronic malabsorption syndrome\n    * Malignancy (non-melanoma skin cancer exempted)\n    * Autoimmune disease\n    * Pregnant, planning to be pregnant, or nursing during the course of the study\n    * Chronic history of recurrent urinary tract infections (UTI) (≥ 3 UTIs per year)\n    * Diagnosis of aneurysm\n    * Indigestion due to hypochlorhydria (low stomach acid)\n    * Any other condition, that in the opinion of the enrolling physician, makes the subject an unsuitable candidate for the study.\n  * Current use of any of the following medications or supplements which could affect safety or compliance with this study:\n\n    * The medical food, KetoCitra®.\n    * Urine alkalizing agents such as sodium bicarbonate or potassium citrate\n    * Citrate treatments\n    * Immunosuppressive treatment\n    * Tolvaptan\n    * Potassium-sparing diuretics\n    * Somatostatin analogs\n    * Aluminum-containing supplements or medications such as aluminum antacids (e.g. Maalox) or aluminum-based phosphate binders.\n    * SGLT2 inhibitors\n  * Participation in another therapeutic intervention trial.\n  * Following a highly specialized or extreme diet that is incompatible with the interventional nutrition program (e.g. carnivore, very high protein diet for elite athletes, etc.)\n  * Food sensitivities or allergies that are incompatible with the interventional nutrition program.\n  * The subject is already adhering to a form of a ketogenic diet or related fasting regimen.\n  * Current or past history of disordered eating or feeding behaviors.\n  * History of gastric bypass.\n  * Active diagnosis of ulcerative colitis, Irritable Bowel Syndrome, Crohn's, or Gallbladder Disease.",{"count":126,"type":20},20,[23],"This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.",[26],[83,131,132,133,134],"polycystic kidneys","Ren-Nu","KetoCitra","Keto diet","2026-03-03",{"date":137,"type":31},"2026-03-06",{"date":139,"type":31},"2026-02-25",{"date":141,"type":20},"2028-02",{"name":143,"class":115},"Richard Fatica",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":83,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":116},"100576512","di-pkd-a-pilot-trial-of-dietary-intervention-in-patients-with-autosomal-dominant-polycystic-kidney-disease-100576512","NCT06786260","Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease","Di-PKD: A Pilot Trial of a 12-Month Targeted Dietary Intervention on Cyst Progression in Patients With Autosomal Dominant Polycystic Kidney Disease","Inclusion Criteria:\n\n* Confirmed diagnosis of ADPKD\n* Genetic testing confirmation of PKD1 or PKD2\n* eGFR \\>30mL\u002F1.73m2\n* Willingness to adhere to a preconditioning diet for 1 week and ability to complete the study\n* Mayo Clinic Imaging Classification (MCIC): 1C, 1D, 1E\n\nExclusion Criteria:\n\n* History of dietary non-adherence\n* Subjects on Tolvaptan\n* Comorbidities that could interfere with participation (Diabetes, Heart Failure (EF\\\u003C30%) Advanced Chronic Kidney Disease (CKD) Stage 4 and higher)",{"count":102,"type":20},[23],"The goal of this interventional study is to evaluate the impact of a specific diet (low salt, limited caffeine, high potassium, low phosphate, limited protein, limited carbohydrate intake, adequate water intake) on changes in serum and urinary biomarkers, total kidney volume (TKV), and cyst progression in subjects with autosomal dominant polycystic kidney disease (ADPKD).\n\nResearchers will compare the results of subjects in the study diet (interventional) arm to the results of subjects in the regular diet (control) arm.",[26],[83,156],"Diet","2026-01-28",{"date":159,"type":31},"2026-01-30",{"date":161,"type":20},"2026-05",{"date":163,"type":20},"2027-04",{"name":165,"class":115},"Loma Linda University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":116},"100612937","hypertension-in-children-and-young-people-at-risk-of-autosomal-dominant-polycystic-kidney-disease-100612937","NCT07260071","Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease","Family Study of Early Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease","HIYA-PKD","Inclusion Criteria:\n\n* Age 12 - 17 years at the time of consent\n* Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test)\n* Parent with confirmed clinical diagnosis of ADPKD\n* Parent (if child \\\u003C16 years) or both parent and young person (if \\>=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this.\n\nExclusion Criteria:\n\n* 18 years or above at the time of study entry\n* Unable to tolerate key study investigations\n* Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations\n* Unwilling to undergo genetic testing for ADPKD","12 Years","17 Years",{"count":177,"type":20},200,"The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance imaging (MRI) for rapid diagnosis alongside genetic testing. The main question it aims to answer is:\n\nWhat is the prevalence of hypertension in a population sample of adolescents with ADPKD?\n\nParticipants will have the following measurements performed:\n\n* Height and weight.\n* Blood pressure.\n* Non-invasive measurement of arterial stiffness.\n* Cardiac and renal MRI.\n* Blood sample.\n* Genetic testing.",[180],"Autosomal Dominant Polycystic Kidney Disease (ADPKD",[182,183,184,185,186,187,188,189],"hypertension","children","young people","autosomal dominant polycystic kidney disease","arterial stiffness","genetic testing","albuminuria","proteinuria","2025-11-20",{"date":192,"type":31},"2025-12-02",{"date":194,"type":31},"2025-08-15",{"date":196,"type":20},"2028-03",{"name":198,"class":115},"King's College London",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100606877","phase-1-drug-drug-interaction-of-jmkx003142-with-amiodarone-and-febuxostat-in-healthy-subjects-100606877","NCT07181265","Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase I Drug-drug Interaction Clinical Study to Evaluate the Pharmacokinetics of JMKX003142 With Amiodarone, and Febuxostat in Chinese Healthy Subjects","Inclusion Criteria:\n\n1. Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.\n2. Healthy adult males and\u002For females, 18 to 45 years of age (inclusive) at the date of signed consent form. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg\u002Fm2) and a minimum body weight of 45 kg.\n3. The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n4. Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm\u002Fegg for the time period specified above.\n\nExclusion Criteria:\n\n1. Subjects having hypersensitivity to study drug or have a history of allergies to multiple drugs, foods, or other substances\n2. History or presence of significant circulatory system, respiratory system, digestive system, blood system, urinary and reproductive system, endocrine and metabolic system, nervous system, mental system, muscular and skeletal system, skin system, lymphatic system, immune system, Otolaryngology or other related systems disease or disorder. as well as systemic or local acute or chronic infections.\n3. Subjects with dysphagia, gastrointestinal diseases, or any conditions that may affect drug absorption; such as a history of hepatobiliary and pancreatic diseases, gastrointestinal diseases, gastrointestinal surgery (except appendectomy), or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.\n4. Vital signs during the screening period meet any of the following conditions: systolic blood pressure \\>140 mmHg or \\\u003C90 mmHg; diastolic blood pressure \\>90 mmHg or \\\u003C50 mmHg (Cohort 1: diastolic blood pressure \\>90 mmHg or \\\u003C60 mmHg); pulse \\>100 beats\u002Fmin or \\\u003C50 beats\u002Fmin (Cohort 1: pulse \\>100 beats\u002Fmin or \\\u003C60 beats\u002Fmin); ear temperature \\>37.5°C or \\\u003C35°C.\n5. History of QTc interval prolongation or abnormal ECG results during screening, QTcF ≥ 450 ms for males or ≥ 470 ms for females, or QRS interval \\> 120 ms.","45 Years",{"count":208,"type":20},48,[77],"This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects",[26],"2025-09-12",{"date":214,"type":31},"2025-09-18",{"date":216,"type":20},"2025-10-30",{"date":218,"type":20},"2026-06-30",{"name":220,"class":64},"Jemincare"]